CAS: 27139-97-5; 2-Bromo-4-Chloro-1-Methylbenzene

上下游产品

CAS号95-79-4 5-氯-2-甲基苯胺 | CAS号106-43-4 对氯甲苯 | CAS号106-38-7 对溴甲苯 | CAS号7745-93-9 2-溴-4-硝基甲苯 | CAS号7745-91-7 3-溴-4-甲基苯胺 | CAS号95-46-5 2-溴甲苯 | CAS号7745-87-1 3-bromo-4-methy... | CAS号936-08-3 2-溴-4-氯苯甲酸 | CAS号5306-98-9 5-氯-2-甲基苯酚 | CAS号58966-34-0 5-氯-2-甲基苯甲醛 | CAS号33924-45-7 2-溴-1-(溴甲基)-4-氯苯 | CAS号80568-28-1 9H-Thioxanthen-... | CAS号80568-29-2 1-(2-dimethylam... | CAS号80568-39-4 9H-Thioxanthen-... | CAS号80568-46-3 6-hydroxy-1-[2-... | CAS号80568-56-5 1-(2-diethylami... | CAS号80568-65-6 9H-Thioxanthen-...

对氯甲苯置于溴,铁粉体系中,化学反应 3.5H,以40%的收率获得2-溴-4-氯甲苯
参考文献:新型非典型抗精神病药:合理的设计,有效的钯催化途径和药理研究.
标题:新型非典型抗精神病药:合理的设计,有效的钯催化途径和药理研究.
摘要:使用合理的药物设计来开发非典型的抗精神病药物候选物,我们产生了具有优化的pk(i)5-Ht(2A)/ D(2)比率的新型且代谢稳定的吡咯并苯并ze庚因.通过新的钯催化的三步合成获得的5A被选择用于进一步的药理和生化研究,并在体内显示出非典型的抗精神病特性.5A具有0.56 Mg / Kg的条件回避反应活性,具有较低的抗感性,并被证明优于st1899,氯氮平和奥氮平,代表了新的临床候选药物.
Doi:10.1021/jm049629T

专利信息

专利号:US-2025179012-A1
优先权日:2022-03-04
标 题:Synthesis of sulfur(vi) compounds and reagents for same
发明人：LOPCHUK JUSTIN MATTHEW; SHULTZ ZACHARY
权利人:H LEE MOFFITT CANCER CT & RES
摘要:This disclosure provides reagents and processes for the synthesis of organic compounds, more particularly reagents and processes for the asymmetric synthesis of sulfur (VI) containing organic compounds.

专利号:US-8487108-B2
优先权日:2005-11-14
标题 :Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors
发明人：BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T
权利人:BALDWIN JOHN J; CLAREMON DAVID A; TICE COLIN; CACATIAN SALVACION; DILLARD LAWRENCE W; ISHCHENKO ALEXEY V; YUAN JING; XU ZHENRONG; MCGEEHAN GERARD; SIMPSON ROBERT D; SINGH SURESH B; ZHAO WEI; FLAHERTY PATRICK T; VITAE PHARMACEUTICALS INC
摘要:The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.

专利号:US-2011301143-A1
优先权日:2009-02-23
标题 :Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
发明人：ISABEL ELISE; LACHANCE NICOLAS; LECLERC JEAN-PHILIPPE; LEGER SERGE; OBALLA RENATA M; POWELL DAVID; RAMTOHUL YEEMAN K; ROY PATRICK; TRANMER GEOFFREY K; ASPIOTIS RENEE; LI LIANHAI; MARTINS EVELYN
权利人:ISABEL ELISE; LACHANCE NICOLAS; LECLERC JEAN-PHILIPPE; LEGER SERGE; OBALLA RENATA M; POWELL DAVID; RAMTOHUL YEEMAN K; ROY PATRICK; TRANMER GEOFFREY K; ASPIOTIS RENEE; LI LIANHAI; MARTINS EVELYN
摘要:Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, Câ•?CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

专利号:US-2012010186-A1
优先权日:2009-03-23
标题:Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
发明人：LACHANCE NICOLAS; LEGER SERGE; OBALLA RENATA M; POWELL DAVID; TRANMER GEOFFREY K; MARTINS EVELYN; GAREAU YVES
权利人:LACHANCE NICOLAS; LEGER SERGE; OBALLA RENATA M; POWELL DAVID; TRANMER GEOFFREY K; MARTINS EVELYN; GAREAU YVES; MERCK FROSST CANADA LTD
摘要:Heterocyclic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer, liver steatosis; and non-alcoholic steatohepatitis.

专利号:WO-0130742-A1
优先权日:1998-11-23
标题:Improved synthesis of racemic sertraline

专利号:EP-1224159-B1
优先权日:1998-11-23
标 题:Improved synthesis of racemic sertraline